Karyopharm announces presentation of updated phase 1 selinexor data in patients with treatment-naÏve myelofibrosis at ash 2022

– a 92% svr35 and a 67% tss50 were observed in the efficacy evaluable patients at week 24 – – 57% of transfusion independent patients achieved hemoglobin stabilization – – company to host investor and analyst webcast featuring key opinion leaderstoday at 8:30 a.m. et – newton, mass.
KPTI Ratings Summary
KPTI Quant Ranking